{"id":164251,"date":"2026-11-22T03:25:20","date_gmt":"2026-11-22T03:25:20","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/164251\/"},"modified":"2026-11-22T03:25:20","modified_gmt":"2026-11-22T03:25:20","slug":"vabysmo-shows-signs-of-recovery-as-roche-gears-up-for-busy-2027","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/164251\/","title":{"rendered":"Vabysmo shows signs of recovery as Roche gears up for busy 2027"},"content":{"rendered":"<p>After disappointing Wall Street for most of 2026, Roche\u2019s eye disease drug Vabysmo met analysts\u2019 expectations for the first time this year. But the company may have bigger fish to fry heading into 2027.<\/p>\n<p>The bispecific antibody of VEGF-A and Ang-2 <a href=\"https:\/\/www.roche.com\/media\/releases\/med-cor-2026-10-22\" rel=\"nofollow noopener\" target=\"_blank\">brought in<\/a> 1.14 billion Swiss francs ($1.38 billion) in third-quarter sales, up 10% sequentially and topping consensus estimates by 2%.<\/p>\n<p>The beat comes as Vabysmo hit a milestone, having treated 1.5 million patients globally, Roche\u2019s pharmaceuticals chief Teresa Graham told investors during a call Thursday.<\/p>\n<p>Vabysmo is a key driver in the 9% year-over-year sales growth at constant exchange rates for Roche\u2019s ophthalmology franchise, as the drug continues market share gains, Graham said. Vabysmo is approved in the U.S. for wet age-related macular degeneration, diabetic macular edema and retinal vein occlusion.\u00a0<\/p>\n<p>\u201cBy now, Vabysmo has established itself as the preferred first-line treatment, including in the U.S.,\u201d she said.<\/p>\n<p>After stellar growth initially, Vabysmo suddenly lost momentum toward the end of 2025. Between the second-quarter 2025 and the second-quarter 2026, sales of the drug actually <a href=\"https:\/\/www.fiercepharma.com\/pharma\/roche-defends-chf-6b-vabysmo-peak-sales-target-despite-another-quarterly-miss\" rel=\"nofollow noopener\" target=\"_blank\">declined<\/a> 1%.\u00a0<\/p>\n<p>Roche previously attributed the deceleration to a reset of the U.S. branded VEGF market after the closure of certain charity copay programs.\u00a0<\/p>\n<p>\u201cI think the U.S. has re-baselined,\u201d Graham said on Thursday\u2019s call. \u201cWe are expecting to remain in that low single-digit growth for Vabysmo in terms of sales.&#8221;<\/p>\n<p>\u201cIt\u2019s probably important to note though that volume growth in the U.S. is much higher\u2014there\u2019s a contracting effect that takes effect here,\u201d she continued. \u201cAnd then, when you look ex-U.S., there is actually significant growth for Vabysmo, and more opportunity for growth and penetration to come outside of the U.S.\u201d<\/p>\n<p>The Roche exec maintained that the current consensus peak sales outlook of 6 billion Swiss francs is \u201cvery reasonable,\u201d and that Vabysmo is on track to achieve that.<\/p>\n<p>As the Vabysmo market stabilizes, Roche and investors are turning their attention to several potential blockbuster launches.\u00a0<\/p>\n<p>The company\u2019s oral SERD drug giredestrant is gearing up for an FDA decision by the end of November. For 2027, Roche is expecting FDA approvals for its KRAS G12C inhibitor divarasib in non-small cell lung cancer, for BTK inhibitor fenebrutinib in multiple sclerosis and sefaxersen in IgA nephropathy, among others. As Graham put it, Roche\u2019s regulatory and launch teams will be \u201cexceptionally busy\u201d in the next few months.\u00a0<\/p>\n<p>None of those will be easy rollouts. For <a href=\"https:\/\/www.fiercepharma.com\/pharma\/roche-pharma-ceo-maintains-oral-serd-could-be-largest-product-company-history-despite-data\" rel=\"nofollow noopener\" target=\"_blank\">giredestrant<\/a>, the company is targeting a first-in-class adjuvant nod for early breast cancer, but as one analyst noted on the call, many doctors remain skeptical and are waiting for overall survival data to be convinced. The phase 3 lidERA trial supporting Roche\u2019s filing will have another overall survival data cutoff toward the first half of 2027, Graham noted.\u00a0<\/p>\n<p>As for another criticism around lidERA\u2019s lack of involvement of a CDK4\/6 inhibitor, Graham said that a single-arm sub-study in combination with Eli Lilly\u2019s Verzenio is expected to read out this year. Roche recently also announced two new studies in the adjuvant setting, including an investigator-initiated study using a ctDNA-guided approach and a phase 1\/3 testing giredestrant alongside Pfizer\u2019s CDK4 candidate atirmociclib.<\/p>\n<p>For <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/roche-orchestrates-phase-3-kras-lung-cancer-win-over-amgen-and-bristol-myers\" rel=\"nofollow noopener\" target=\"_blank\">divarasib<\/a>, Roche will need to compete with existing KRAS inhibitors, Amgen\u2019s Lumakras and Bristol Myers Squibb\u2019s Krazati. After seeing \u201cstrong\u201d phase 3 data, to be presented at the European Society for Medical Oncology 2026 Congress this weekend, Roche has increased divarasib\u2019s peak sales guidance to between 2 billion and 3 billion Swiss francs, Roche\u2019s CEO Thomas Schinecker said on the call.<\/p>\n<p>In the BTK field, Roche\u2019s fenebrutinib is on a collision course with Novartis\u2019 <a href=\"https:\/\/www.fiercepharma.com\/pharma\/novartis-claims-ms-win-rhapsido-remibrutinib-clears-phase-3-no-liver-safety-signal\" rel=\"nofollow noopener\" target=\"_blank\">Rhapsido<\/a> in MS. It\u2019s also not entirely clear how the oral BTK space will play out against antibody drugs such as Roche\u2019s top-selling Ocrevus, although Graham argued fenebrutinib \u201cwill ultimately just crack up a whole new market segment,\u201d rather than chipping away Ocrevus\u2019 market.\u00a0<\/p>\n<p>As for IgAN, the space has become crowded with multiple options across various mechanisms of action, including a new FDA nod Wednesday for AstraZeneca\u2019s complement inhibitor Ultomiris.\u00a0<\/p>\n<p>Despite the upcoming launches, one analyst on the call questioned Roche\u2019s ability to maintain the same level of revenue growth in 2027, pointing to \u201cgrowth pressures or slowdowns on a number of products.\u201d In the first nine months of 2026, Roche\u2019s pharmaceuticals division ginned up 36.2 billion Swiss francs ($44 billion) on the strength of a 7% year-over-year increase at constant exchange rates, and the entire group\u2019s 46.5 billion Swiss francs marked 6% growth.\u00a0<\/p>\n<p>\u201cI can only say that we\u2019re confident that we can maintain a similar momentum that we have,\u201d Schinecker said on the call, adding that profit margins are expected to be \u201cat least stable.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"After disappointing Wall Street for most of 2026, Roche\u2019s eye disease drug Vabysmo met analysts\u2019 expectations for the&hellip;\n","protected":false},"author":2,"featured_media":164252,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[76049,70157,230,41939,625,19768,2536,31756,134,32276],"class_list":["post-164251","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-drug-launch","tag-drug-sales","tag-earnings","tag-fierce-pharma-homepage","tag-financials","tag-launches","tag-pharma","tag-quarterly-sales","tag-roche","tag-vabysmo"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117657961951287644","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/164251","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=164251"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/164251\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/164252"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=164251"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=164251"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=164251"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}